Association of Paraoxonase-1 Activity and Concentration With Angiographic Severity and Extent of Coronary Artery Disease

Journal of the American College of Cardiology

Volumn 47, Issue 12, 2006, Pages 2429-2435

  Granér, Marit ^a   James, Richard W ^b   Kahri, Juhani ^a   Nieminen, Markku S ^a   Syvänne, Mikko ^a   Taskinen, Marja Riitta ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HEART CATHETERIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OXIDATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SMOKING;

ARYLDIALKYLPHOSPHATASE; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 33744993389     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.01.074     Document Type: Article

References (43)

1. Miller G.J., and Miller N.E. Plasma high-density lipoprotein concentration and the development of ischaemic heart disease. Lancet 1 (1975) 16-19
2. Gordon D.J., and Rifkind B.M. High-density lipoprotein-the clinical implications or recent studies. N Engl J Med 321 (1989) 1311-1316
3. Steinberg D., Parthasarathy S., Carew T., Khoo J.L., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increases atherogenicity. N Engl J Med 320 (1998) 933-937
4. Lusis A.L. Atherosclerosis. Nature 407 (2000) 233-241
5. Mackness M.I., Abbott C.A., Arrol S., and Durrington P.N. The role of high density lipoprotein and lipid soluble antioxidant vitamins in inhibiting low density lipoprotein oxidation. Biochem J 294 (1993) 829-834
6. Parthasarathy S., Barnett J., and Fong L.G. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1044 (1990) 275-283
7. Mackness M.I., Arrol S., Abbott C.A., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 (1993) 129-135
8. Watson A.D., Berliner J.A., Hama S.Y., et al. Protective effect of high-density lipoprotein associated paraoxonase. inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995) 2882-2891
9. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions. a possible peroxidative role for paraoxonase. J Clin Invest 101 (1998) 1581-1590
10. Shih D.M., Gu L., Xia Y.-R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
11. Tward A., Xia Y.R., Wang X.P., et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106 (2002) 484-490
12. Leviev I., and James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20 (2000) 516-521
13. Wheeler J.G., Keavney B.D., Watkins H., Collins R., and Danesh J. Four paraoxonase gene polymorphisms in 11,212 cases of coronary heart disease and 12,786 controls. meta-analysis of 43 studies. Lancet 363 (2004) 689-695
14. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 21 (2001) 1451-1457
15. Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation 107 (2003) 2775-2779
16. Azarsiz E., Kayikcioglu M., Payzin S., and Sözmen E.Y. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int J Cardiol 91 (2003) 43-51
17. Reiber J.H.C., van der Zwet P.M.J., von Land C.D., et al. Quantitative coronary arteriography. equipment and technical requirements. In: Reiber J.H.C., and Serreyus P.W. (Eds). Advances in Quantitative Coronary Arteriography (1993), Kluwer Academic Publishers, Dordecht 75-111
18. Pajunen P., Nieminen M.S., Taskinen M.R., and Syvänne M. Quantitative comparison of angiographic characteristics of coronary artery disease in patients with noninsulin-dependent diabetes mellitus compared with matched nondiabetic control subjects. Am J Cardiol 80 (1997) 550-556
19. Taskinen M.R., Kuusi T., Helve E., Nikkila E.A., and Yki-Järvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 8 (1988) 168-177
20. Parra H.J., Mezdour H., Ghalim N., Bard J.M., and Fruchart J.C. Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to use plates. Clin Chem 36 (1990) 1431-1435
21. Blatter Garin M.C., Abbott C., Messmer S., et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay. population differences in protein concentrations. Biochem J 304 (1994) 549-554
22. Blatter Garin M.C., James R.W., Dussoix P., et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99 (1997) 62-66
23. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1. Diagnosis and Classification of Diabetes Mellitus. WHO/NCD/NCS/99.2 (1999), World Health Organization, Geneva
24. Chen Q., Reis S.E., Kammerer C.M., et al. Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood-Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 72 (2003) 13-22
25. Mueller R.F., Hornung S., Furlong C.E., Anderson J., Giblett E.R., and Motulsky A.G. Plasma paraoxonase polymorphism. a new enzyme assay, population, family, biochemical and linkage studies. Am J Hum Genet 35 (1983) 393-408
26. Richter R.J., and Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9 (1999) 745-753
27. Adkins S., Gan K.N., Mody M., and La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase. glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52 (1993) 598-608
28. Aviram M., Sorenson R., Bisgaier C., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities. Arterioscler Thromb Vasc Biol 18 (1998) 1617-1624
29. Cao H., Girard-Globa A., Berthezene F., and Moulin F. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J Lipid Res 40 (1999) 133-139
30. La Du B.N. Future studies of low-activity PON1 phenotype subjects may reveal how PON1 protects against cardiovascular disease. Arterioscler Thromb Vasc Biol 23 (2003) 1317-1318
31. Sutherland W.H.F., Walker R.J., de Jong S.A., van Rij A.M., Phillips V., and Walker H.L. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol 19 (1999) 1340-1347
32. Kaplan M., Hayek T., Raz A., et al. Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 131 (2001) 2082-2089
33. van der Gaag M.S., van Tol A., Scheek L.M., et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 147 (1999) 405-410
34. James R.W., Leviev I., and Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in coronary artery disease patients. Circulation 101 (2000) 2252-2257
35. Sozmen E.Y., Mackness B., Sozmen B., et al. Effect of organophosphate intoxication on human serum paraoxonase. Hum Exp Toxicol 21 (2002) 247-252
36. Serhatlioglu S., Gursu M.F., Gulcu F., Canatan H., and Godekmerdan A. Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation. Cell Biochem Funct 21 (2003) 371-375
37. Mackness M.I., Harty D., Bhatnagar D., et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 86 (1991) 193-198
38. Abbott C.A., Mackness M.I., Kumar S., Boulton A.J., and Durrington P.N. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioslcer Thromb Vasc Biol 15 (1995) 1812-1818
39. Hasselwander O., McMaster D., Fogarty D.G., et al. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 44 (1998) 179-181
40. Blatter M.C., James R.W., Messmer S., Barja F., and Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Eur J Biochem 211 (1993) 871-879
41. La Du B.N., and Novais J. Human serum organophosphatase. biochemical characteristics and polymorphic inheritance. In: Reiner E., Aldridge W.N., and Hoskin C.G. (Eds). Enzymes Hydrolysing Organophosphorus Compounds (1989), Ellis Horwood, England 41-52
42. Boman H. Cholinesterase, arylesterase and lipoproteins in twins. Acta Genet Med Gemellol 29 (1980) 281-287
43. Rozek L.S., Hatsukami T.S., Richter R.J., et al. The correlation of paraoxonase (PON1) activity with lipid and lipoprotein levels differs with vascular disease status. J Lipid Res 46 (2005) 1888-1895